Abstract

Amphetamine positive urine toxicology screens can lead to diagnostic challenges, especially when there is no known exposure to illicit substances. Atomoxetine, a selective norepinephrine reuptake inhibitor commonly prescribed for attention-deficit/hyperactivity disorder, has been rarely associated with false-positive urine drug screens for amphetamines. In this case report, we present a clinical scenario in which a patient undergoing routine urine toxicology screening tested positive for amphetamines, despite no history of amphetamine use. Through a comprehensive analysis of the available literature, we explore the potential mechanisms behind the false-positive result and highlight the importance of accurate interpretation of urine toxicology screening results in patients taking atomoxetine.